If confirmed in future rigorously designed studies, GLP-1 RAs may address a major treatment gap in AUD, particularly for patients with coexisting obesity or diabetes, two populations often underserved by conventional AUD therapies. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.